Payment overview · 2025
General Payments
$1,234.84
47 reported records · 16 companies
Healthcare provider profile · identity verified
Raman Ashta, MD
Allopathic & Osteopathic Physicians|Family Medicine · MELBOURNE, FL · NPI 1144496993
Verified facts
What the public records show
CMS Open Payments records show Raman Ashta, MD received $1,234.84 in general payments during 2025 across 47 reported records.
Novo Nordisk Inc accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Paxlovid, Synthroid, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $195.80 | 15.9% | 11 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $181.44 | 14.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $154.94 | 12.6% | 8 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $111.58 | 9.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $105.36 | 8.5% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $99.00 | 8.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $92.45 | 7.5% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.09 | 4.7% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $47.97 | 3.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $46.11 | 3.7% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $41.65 | 3.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.69 | 2.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$21.84 | 1.8% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $15.99 | 1.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.34 | 1.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $14.59 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,135.84 | 46 |
| Education | $99.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $181.44 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $111.58 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $92.45 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $92.07 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $85.35 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $78.47 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $78.47 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $68.08 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $58.46 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $58.09 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $47.97 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $46.11 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $41.65 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $40.80 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $39.08 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.69 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $14.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 72 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 70 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 84 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 24 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 51 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
70 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
82 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 527 | 160 |
| Amlodipine Besylate | Amlodipine Besylate | 439 | 132 |
| Losartan Potassium | Losartan Potassium | 373 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 318 | 93 |
| Lisinopril | Lisinopril | 239 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 219 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 206 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 59 |
| Metformin Hcl | Metformin Hcl | 157 | 48 |
| Alprazolam | Alprazolam | 151 | 39 |
| Gabapentin | Gabapentin | 141 | 49 |
| Metformin Hcl Er | Metformin Hcl | 135 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 40 |
| Omeprazole | Omeprazole | 114 | 40 |
| Furosemide | Furosemide | 112 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 28 |
| Simvastatin | Simvastatin | 96 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 38 |
| Mirtazapine | Mirtazapine | 84 | 25 |
| Ozempic | Semaglutide | 84 | 20 |
| Eliquis | Apixaban | 82 | 21 |
| Carvedilol | Carvedilol | 72 | 21 |
| Jardiance | Empagliflozin | 72 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 24 |
| Mounjaro | Tirzepatide | 70 | 16 |
| Sertraline Hcl | Sertraline Hcl | 69 | 21 |
| Allopurinol | Allopurinol | 66 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 23 |
| Alendronate Sodium | Alendronate Sodium | 63 | 24 |
| Potassium Chloride | Potassium Chloride | 63 | 24 |
| Trazodone Hcl | Trazodone Hcl | 62 | 21 |
| Bupropion Xl | Bupropion Hcl | 57 | 19 |
| Tramadol Hcl | Tramadol Hcl | 56 | 17 |
| Montelukast Sodium | Montelukast Sodium | 54 | 19 |
| Atenolol | Atenolol | 53 | 15 |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 15 |
| Synthroid | Levothyroxine Sodium | 51 | 15 |
| Glimepiride | Glimepiride | 46 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | suppressed |
| Famotidine | Famotidine | 45 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 14 |
| Lorazepam | Lorazepam | 41 | 15 |
| Pregabalin | Pregabalin | 41 | 11 |
| Spironolactone | Spironolactone | 38 | suppressed |
| Lovastatin | Lovastatin | 36 | suppressed |
| Meloxicam | Meloxicam | 36 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 32 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | 17 |
| Methylprednisolone | Methylprednisolone | 30 | 28 |
| Prednisone | Prednisone | 30 | 20 |
| Cephalexin | Cephalexin | 29 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 14 |
| Praluent Pen | Alirocumab | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | 12 |
| Clonazepam | Clonazepam | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 22 |
| Finasteride | Finasteride | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | 11 |
| Fluconazole | Fluconazole | 18 | 11 |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 13 |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 11 |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Cefdinir | Cefdinir | 13 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 12 |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,234.84 · 47 records | Novo Nordisk Inc | BREZTRI, COMIRNATY, Cologuard Collection Kit, FREESTYLE LIBRE 3, INCEPTIV, JARDIANCE, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, Quviviq, REPATHA, SYNTHROID, TZIELD, UBRELVY, VOQUEZNA, WATCHMAN FLX, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error